Standard zinc supplementation had limited impact on muscle health or zinc levels in boys with Duchenne muscular dystrophy, highlighting the need for more tailored nutritional strategies.
A clinical trial investigating oral zinc supplementation in boys with Duchenne muscular dystrophy (DMD) found the treatment did not significantly improve key health measures.1
Published in Nutrients, the study focused on zinc’s role in muscle health and cellular function and aimed to assess changes in bioelectrical impedance parameters, which are indicators of muscle integrity, body composition, and hydration. Despite its potential, zinc supplementation showed limited benefits, raising concerns about the adequacy of current nutritional recommendations for patients with DMD.
The researchers found that nearly 30% of the 33 boys in the study, aged 5 to 24, had zinc levels below the healthy range at the start, indicating a risk of zinc deficiency. After 4 months of supplementation, while zinc supplementation slightly reduced the percentage of boys with low zinc levels to 20%, the change was not statistically significant. There were also no statistically significant changes in muscle function or hydration measures such as phase angle (PA) and bioelectrical impedance vector analysis (BIVA), which monitor cellular health and body composition.
“DMD is a progressive neurodegenerative disease that induces permanent changes in muscle cell membranes,” the study authors said, pointing to the unique challenges of treating children with DMD. “Therefore, zinc supplementation may not be enough to alter or improve the measured parameters.”
Zinc plays a crucial role in maintaining cell membranes and supporting muscle function. However, researchers found that the muscle damage caused by DMD may limit zinc’s effectiveness. PA and BIVA results showed a decline in muscle health with age, and the study confirmed that these measures were not improved by zinc supplementation. The absence of changes in these parameters suggests that DMD’s progressive muscle deterioration requires more targeted interventions.
Zinc is an essential trace mineral required in small amounts but vital for nearly 100 enzymes that support critical bodily functions, including cell growth, DNA creation, tissue repair, and immune function.2 It plays a key role during periods of rapid growth, such as childhood, adolescence, and pregnancy when adequate zinc intake is essential for healthy development. The current recommended daily amount of zinc in adults is generally 11 mg a day for men and 8 mg for women, with an upper limit of 40 mg per day.3 The recommended dose ranges from 3 to 8 mg for children depending on age, and 9 to 11 mg for teens.
“Given inflammation and lean mass loss in DMD, doses higher than those recommended for zinc are likely necessary to achieve an effect on the measured parameters,” the study authors said.1
Beyond the limited effectiveness of zinc supplements, the study also pointed to the usefulness of bioelectrical impedance measures like PA and BIVA in monitoring the health of patients with DMD. These tools can help track changes in body composition and detect worsening muscle loss, offering insights into disease progression and potential interventions.
The authors noted that future studies should include a more representative sample with a longer study period to determine the generalizability of these findings.
“Considering the functions of zinc and the pathophysiology of DMD, it is essential to implement strategies to prevent or treat zinc deficiency in this population,” the authors added. “Further studies investigating larger and safer doses of oral zinc supplementation are warranted.”
References
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis
September 26th 2024In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Read More
Atrial Arrhythmias Common in DMD, but More Data on Treatment Are Needed
September 18th 2024Cases of atrial arrhythmia in patients with Duchenne muscular dystrophy (DMD) are common but lack a standard solution, and more long-term data on the management of arrhythmias in DMD are needed.
Read More
Novel Imaging Algorithm Shows Promise in DMD Evaluation
September 6th 2024Measurements on a standard phantom and a clinical data set of patients with Duchenne muscular dystrophy (DMD) were used to validate a novel robust reference frequency method approach, which outperformed typical imaging strategies.
Read More